针对乳腺癌中的YBX1蛋白与蛋白相互作用网络的黄类药物的综合性研究:从计算分析到实验验证
Presanna Kumar Sreelekshmi1, Suresh Kumar Pooja2, Niranjan Vidya2
1Department of Biochemistry and Molecular Biology, Central University of Kerala, Periye, Kasargod, Kerala, 671320, India.
Molecular biotechnology
|November 20, 2024
概括
像奎尔塞和菲塞这样的黄类化合物显示出向Y盒结合蛋白1 (YBX1) 相互作用的潜力. 这项研究探讨了破坏YBX1的自然化合物.
科学领域:
- 生物化学 生物化学
- 分子生物学分子生物学
- 药理学 药理学是指药理学的学科.
背景情况:
- Y-box-binding protein 1 (YBX1) 是一种型蛋白质,涉及乳腺癌的化疗耐药性和转移.
- 关于YBX1的蛋白质与蛋白质相互作用 (PPI) 的研究有限,阻碍了治疗的发展.
- 黄素具有抗癌性质和低毒性,使其成为有前途的治疗剂.
研究的目的:
- 为了研究YBX1蛋白质与蛋白质相互作用 (PPI) 网络.
- 评估选择的黄素 (Quercetin,Fisetin,Rutin,Myricitrin) 在准YBX1 PPI中的潜力.
- 提供对YBX1驱动癌症新型治疗策略的见解.
主要方法:
- 计算分析包括26个对接会,针对特定的YBX1相互作用蛋白 (HSPA1A,IGF2BP1,MECP2,G3BP1,EWSR1,PURA,SYNCRIP).
- 用ADMET和分子动力学 (MD) 模拟来评估黄类药物的药物相似性和稳定性.
- 使用MCF-7细胞进行体外研究,以确定黄类药物对YBX1表达的影响.
主要成果:
- 根据ADMET和MD模拟,奎尔塞丁和菲塞丁与鲁丁和密里西特林相比,表现出有利的药物相似性和稳定性.
- 奎尔赛丁和菲赛显著降低了YBX1表达的剂量依赖方式在MCF-7细胞.
- 对YBX1 PPI网络的初步理解以及黄类药物破坏这些相互作用的潜力.
结论:
- 黄类化合物,特别是奎尔赛丁和菲赛丁,显示出作为YBX1 PPI的抑制剂的希望.
- 这项研究支持开发基于黄类药物治疗由YBX1.1驱动的癌症的治疗方法.
- 对YBX1 PPI调节的进一步研究可能会导致新的抗癌策略.
更多相关视频
13:18Network Pharmacology Prediction and Experimental Validation of Trichosanthes-Fritillaria thunbergii Action Mechanism Against Lung Adenocarcinoma
Published on: March 3, 2023
1.2K
07:20Author Spotlight: Integrating Traditional Chinese Medicine with Modern Pharmacology and Genomics for Assessing Postmenopausal Osteoporosis in Mice
Published on: August 23, 2024
444
相关概念视频
Cancer Prevention
6.1K
Several factors can increase the risk of cancer in an individual. About 50% of cancer cases can be prevented by adopting a healthy lifestyle, regular exercise, eating healthy, and following a modest cancer prevention diet. Epidemiological studies have consistently shown that populations with vegetable and fruit-rich diets have reduced the incidence of cancer. On the other hand, populations who have a diet rich in animal fat, red meat, junk food, or high calories are predisposed to cancer.
Some...
Some...
6.1K
The Intrinsic Apoptotic Pathway
6.4K
Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...
6.4K
Combination Therapies and Personalized Medicine
4.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K
